Neflamapimod Fails to Improve Memory But Shows Impact on Tau Levels in Phase 2b Study, EIP Pharma Announces
A Phase 2b study of oral neflamapimod in treating mild Alzheimer’s disease met its secondary goals of statistically significant drops in phospho-tau and tau protein levels in the cerebrospinal fluid (CSF) of treated patients compared to those given a placebo, EIP Pharma announced. But the trial failed to show evidence of…